Lindsay Logan, on Oct 30, 2019 12:55:00 PM
What is your role?
I am a manufacturing technician with a focus on compounding and filling.
How long have you been with Alcami?
I have been with Alcami since June of 2018.
What is the most rewarding part of your job?
The most rewarding parts of my job are taking a product from start to finish, and knowing that I had a direct part in improving the quality of life for others.
Alcami Corporation, on Oct 15, 2019 11:24:01 AM
Alcami will be exhibiting at AAPS 2019 PharmSci 360, to be held November 3 - 6 in San Antonio, Texas. Schedule a meeting or stop by booth #1511 to connect with our team.
Alcami Corporation, on Oct 9, 2019 10:00:00 AM
Alcami will be exhibiting at CPhI Worldwide, to be held November 5 - 7 in Frankfurt, Germany. Schedule a meeting or stop by booth #121C31 to connect with our team.
Jonathan Granger, on Oct 8, 2019 9:44:00 AM
Durham, NC (USA) – October 8, 2019 – Alcami Corporation, a leading provider of fully-integrated custom end-to-end solutions for the pharmaceutical and biologics industries, today announced the launch of its new rapid sterility offering, a service that leverages cutting-edge microbiological testing technology to deliver significantly faster testing results to clients. Alcami invested in the Milliflex® Rapid System for the rapid sterility test, which uses adenosine triphosphate (ATP) bioluminescence for detection of microorganisms after five days.
Stacey Ramsey, MS SM (NRCM), on Sep 30, 2019 10:52:15 AM
Rapid sterility is an alternative test method to the US Pharmacopeia (USP) General Chapter <71>, Ph.Eur. 2.6.1, and JP 4.06 sterility tests that allows for shorter incubation periods and faster results. Alcami is launching rapid sterility via the Milliflex® Rapid System, which uses adenosine triphosphate (ATP) bioluminescence for detection of microorganisms after five days. A fully comprehensive comparability study verifies adherence to USP/Ph.Eur. requirements for alternative microbiological methods and demonstrates that rapid sterility is a reliable alternative to the reference method.
In this webinar, Alcami’s rapid sterility expert, Stacey Ramsey, will introduce Alcami’s new rapid sterility platform and provide information for understanding implementation requirements. Stacey will also discuss the advantages of the rapid sterility platform as it compares to USP <71>.
Imran Ahmed, on Sep 26, 2019 10:30:00 AM
Dr. Imran Ahmed, Head of Formulation Development at Alcami, recently published an article in Pharma Tech Outlook. The article, The Changing R&D Landscape: Emerging Technology Needs and Value Proposition for Strategic Partnerships with Contract Development and Manufacturing Organizations (CDMOs), explains that as a result of pharmaceutical products becoming increasingly complex, new regulatory and manufacturing challenges are on the rise.
Excerpt from Ahmed: "The pharmaceutical product landscape is rapidly and fundamentally changing with profound impact on research and development strategy and technology needs. After a precipitous fall in new drug approvals during the last two decade of the 20th century, there has been a gradual recovery going into the second decade of the 21st century."
Dr. David Molyneux, on Sep 19, 2019 10:30:00 AM
Alcami recently contributed to a special feature in The Medicine Maker magazine, titled "How to Find Your Secret Source."
Excerpt from Alcami: “I have a point of contention with the titles ‘one-stop shop' or 'specialist supply chain’ because they imply that you can’t have both! If you have independent API and drug product, you can bring these together. Being that we were founded by merging two specialized organizations, we have experts in each area, which we then over arch with a structured offering to make sure they are properly integrated. A key thing our clients tell us – especially smaller clients who don’t want to manage a big supply chain – is that they like the internal efficiencies you can get with a one-stop shop."
Cheryl Johnson, on Sep 17, 2019 11:15:14 AM
Biosimilars are sometimes incorrectly considered equivalent to a generic small molecule therapeutic, but for a biologic drug product, the clinical and regulatory pathways are quite different. Alcami Commercial Development Manager Cheryl Johnson explains the distinct differences in the FDA’s definition, development strategy, and regulatory approval pathways.
Angela Moore, on Sep 12, 2019 4:03:00 PM
Alcami recently contributed to an eBook produced by Drug Development and Delivery. The eBook, titled "Analytical Testing in Drug Development," features four companies and explains how they each help the pharmaceutical and biotech industries comply with drug development regulatory requirements.
Angela Moore, abuse-deterrence studies subject matter expert at Alcami, contributed to the eBook. Her article focuses on considerations for abuse-deterrent Category 1 studies as well as standard syringeability studies.
Stacey Ramsey, MS SM (NRCM), on Sep 9, 2019 10:45:00 AM
Join Alcami on Wednesday, September 18, 2019 to learn more about rapid sterility.
Rapid sterility is an alternative test method to the US Pharmacopeia (USP) General Chapter <71>, Ph.Eur. 2.6.1, and JP 4.06 sterility tests that allows for shorter incubation periods and faster results. Alcami is launching rapid sterility via the Milliflex® Rapid System, which uses adenosine triphosphate (ATP) bioluminescence for detection of microorganisms after 5 days. A fully comprehensive comparability study verifies adherence to USP/Ph.Eur. requirements for alternative microbiological methods and demonstrates that rapid sterility is a reliable alternative to the reference method.
In this webinar, Alcami’s rapid sterility expert, Stacey Ramsey, will introduce Alcami’s new rapid sterility platform and provide information for understanding implementation requirements. Stacey will also discuss the advantages of the rapid sterility platform as it compares to USP <71>.
